Clinical Trial Update: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor [Phase 3]

View source ↗

Summary

Phase 3 trial of Orforglipron (LY3502970) in adults with type 2 diabetes and inadequate glycemic control on insulin glargine (with or without metformin and/or S…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Orforglipron (orforglipron)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED